• EksoHealth
  • EksoWorks
  • Company
  • EksoPulse
  • About Us
  • Leadership
  • Events
  • Careers
  • Investors
  • News
Investors

    Investors

  • Overview
  • Company Presentations
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Financials and Filings
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • News / Events

  • Press Releases
  • IR Calendar
  • Email Alerts

Press Releases

  • All News
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014

Ekso Bionics Reports Third Quarter 2017 Financial Results

Nov 8, 2017

Ekso Bionics® to Report Third Quarter 2017 Financial Results on November 8, 2017

Nov 1, 2017

Ekso Bionics® to Showcase the Latest Features of the EksoGT™ Wearable Exoskeleton at 2017 AAPM&R Annual Assembly

Oct 10, 2017

Ekso Bionics Appoints Ted Wang to its Board of Directors

Sep 22, 2017

Ekso Bionics and Genesis Rehab Services Collaborate on Entry into Post-Acute Care Settings

Sep 14, 2017

Ekso Bionics® to Present at WearRAcon 2017 in Beijing, China

Sep 12, 2017

Ekso Bionics® Raises $34 Million in Fully-Financed Rights Offering

Sep 7, 2017

Ekso Bionics Announces Appointment of Christian Babini as Vice President of Sales, Americas

Aug 30, 2017

Ekso Bionics Reminds Shareholders Rights Offering Will Expire at 5:00pm ET on August 31, 2017

Aug 28, 2017

Ekso Bionics® Announces Commencement of $34 Million Rights Offering

Aug 14, 2017
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...18
    Language
    •  English
      •  Deutsch
      •  Français
      •  Español
      •  简体中文
      •  Italiano

    Company

    • About Us
    • Leadership
    • Events
    • Careers
    • Investors
    • News

    Eksohealth

    • EksoGT
      • For Patients
      • For Clinicians
      • For Administrators
    • Find a Center

    Eksohealth

    • Support
      • Contact Us
      • EksoPulse

    Eksoworks

    • Home
    • EksoVest
    • EksoZeroG
    • Support

    ©2011-2019 Ekso Bionics Privacy Policy Cookie Declaration

    Indications for Use (USA)
    The Ekso™ (version 1.1) and EksoGT™ (version 1.2) are intended to perform ambulatory functions in rehabilitation institutions under the supervision of a trained physical therapist for the following populations:
    • Individuals with hemiplegia due to stroke (upper extremity motor function of at least 4/5 in at least one arm)
    • Individuals with spinal cord injuries at levels T4 to L5 (upper extremity motor function of at least 4/5 in both arms)
    • Individuals with spinal cord injuries at levels of C7 to T3 (ASIA D with upper extremity motor function of at least 4/5 in both arms)
    The therapist must complete a training program prior to the use of the device. The devices are not intended for sports or stair climbing.
    Source: FDA Part 21 CFR
    Indications for Use (EU)

    • The Ekso GT™ (Version 1.2) is intended for use as gait training device to improve walking function and independence in patients with a neurological or muscular injury, illness, or weakness.
    • The Ekso GT™ (Version 1.2) is designed to be used in a controlled clinical or non-clinical setting under supervision of Ekso Certified Physical Therapist (or equivalent medical professional) and operated by a Trained Spotter.
    • The Ekso GT™ (Version 1.2) is a device intended to help facilitate the restoration or improvement of ambulation for its pilots. The device is intended to serve multiple pilots over the duration of its life.
    • The Ekso GT™ (Version 1.2) is used to manipulate the legs of a patient and move them through the normal walking gait, from the sit-to-stand position and from standing back to sitting.

    Source: Intended Use – Council Directive 93/42/EEC, Annex II